

SLCTR/2008/018 - Effect of alendronate or calcium plus vitamin D3 on thalassemic osteopathy; an open labelled single blind clinical trial

Progress report 1 - Submitted date: 7th April 2009

Base line data collection of the above study was completed and found to have that 35% of the population had osteopathy. Recruitment to the intervention trial was commenced on mid of March 2009. Up to now 25% of the sample has been recruited for the study.

Initially study was designed as an open labeled single blind clinical trial. Patients in one of the two arms of the study receive calcium and vitamin D3 and other arm receive alendronate.

Since calcium and vitamin D3 therapy is included in the guidelines in the management of thalassemic osteopathy we have decided to administer calcium and vitamin D3 for the both arms.

Patients in one arm receive alendronate and other arm receive placebo. Both patients and investigators are blind to the treatment groups.

Therefore the design of the study is **randomized placebo controlled double blind clinical trial**.